Pharmacogenetic Dosage Algorithm for Acenocoumarol

Plain-language summary

This study evaluated a pharmacogenetic (genetics-based) dosing algorithm to determine the dose of Acenocoumarol, a blood-thinning medication. It included patients on a stable dose of Acenocoumarol for atrial fibrillation, venous thromboembolic disease or heart valve replacement. It was a non-phase study that has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Instituto de Investigación Hospital Universitario La Paz

Intervention

Acenocoumarol

Start date

10/1/2011

Estimated completion

10/1/2013

Countries

Spain

Related genes

Locations

• Madrid, Spain

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patients with Auricular fibrillation, venous thromboembolic disease and cardiac valve replacement receiving acenocoumarol.
* Patients with stable dose of acenocoumarol (weekly dose variation of \<20% in the last 3 months).
* Patients with an international normalised ratio within the range of 2 to 3 (in Auricular Fibrillation and venous thromboembolic disease) or 2.5 to 3.5 (in cardiac valve replacement) for at least the 3 previous consecutive months.

Exclusion Criteria:

* Patients with renal failure (calculated creatinine clearance ≤30 ml/min), hepatic disease (stage C of Child Plough Stage), thyroid dysfunction and/or cancer.